Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Scores 1st US Nod for Ultra-Rare Blood Clotting Disorder
November 13, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
November 10, 2023
- Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
- Mitsubishi Licenses Neuropsychiatric Drug to Dutch Startup Kynexis
November 9, 2023
- Japan Ethical Drug Sales Up 6.8% in September: Crecon
November 9, 2023
- Japan OB/GYN Market Projected at 100 Billion Yen in FY2026: Fuji Keizai
November 9, 2023
- CSL Launches Original Home Delivery Service for Hizentra
November 8, 2023
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
- Keytruda Snares Title in Japan Sales Ranking in October: Encise
November 8, 2023
- 180 Employees Apply for Santen’s Voluntary Buyout Program
November 8, 2023
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
November 7, 2023
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Nobelpharma Seeks Provisional Disposition against Sawai’s Nobelzin Copy
November 7, 2023
- Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
November 7, 2023
- BMS Seeks to Block Sawai’s Sprycel Generic over CML Use
November 7, 2023
- Xocova Claims 1st Trophy in August GP Promotion, Dayvigo Makes Comeback in HP List
November 6, 2023
- Kazunari Tsunaba Steps Down as CEO of Aculys Pharma
November 6, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…